CALGB 10403与COG AALL0232在年轻成人急性淋巴细胞白血病中的毒性比较
CALGB 10403是评估40岁以下年轻成人急性淋巴细胞白血病(ALL)采用儿童启发方案可行性的最大前瞻性研究。本文比较CALGB 10403与COG AALL0232同臂年轻成人患者的毒性事件,发现总体毒性相似,但CALGB 10403中高血糖、高胆红素血症、转氨酶升高和发热性中性粒细胞减少更常见,且不良事件与体重指数≥30 kg/m2及年龄增长相关。CALGB 10403死亡率低(4%),与COG AALL0232相似。
要点
- CALGB 10403方案毒性总体与COG AALL0232相似,但部分3-4级不良事件更常见。
- 高血糖、高胆红素血症、转氨酶升高和发热性中性粒细胞减少在CALGB 10403中更常报告。
- 不良事件与BMI≥30 kg/m2及年龄增长相关,CALGB 10403死亡率4%。
核心结论
- CALGB 10403方案在年轻成人ALL中的毒性事件与COG AALL0232相似,但部分3-4级不良事件更常见。
- CALGB 10403死亡率低(4%),与COG AALL0232试验相似。
- CALGB 10403方案因较历史对照改善生存,现已成为标准治疗。
研究设计与样本
- CALGB 10403是评估40岁以下年轻成人ALL采用儿童方案可行性的最大前瞻性研究。
- 比较CALGB 10403与COG AALL0232同臂年轻成人患者的毒性事件。
主要发现
- CALGB 10403中高血糖、高胆红素血症、转氨酶升高和发热性中性粒细胞减少等3-4级不良事件较COG AALL0232更常报告。
- 不良事件与体重指数≥30 kg/m2相关,部分与年龄增长相关。
- CALGB 10403死亡率4%,与COG AALL0232试验相似。
- CALGB 10403仅39%患者完成全部计划方案治疗;COG AALL0232中<18岁患者74%完成治疗,≥18岁患者仅57%完成治疗。
临床怎么用
- CALGB 10403方案已成为年轻成人ALL的标准治疗。
- 随着对该方案熟悉度增加,希望方案完成率提高。
局限性
- CALGB 10403仅39%患者完成全部计划方案治疗,分析需谨慎解读。
- 年龄和治疗医师相关因素可能影响方案完成情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adolescents and young adults (AYAs) with acute lymphoblastic leukemia have improved outcomes when treated with pediatric-inspired regimens. CALGB 10403 was the largest prospective study to evaluate the feasibility of using a pediatric regimen in AYAs with acute lymphoblastic leukemia up to 40 years of age. This article presents the toxicity events observed in the CALGB 10403 study and compares these toxicities vs those observed among AYAs treated on the same arm of the companion Children's Oncology Group (COG) AALL0232 study. Toxicities in CALGB 10403 were similar to those observed in COG AALL0232. Some grade 3 to 4 adverse events were more often reported in CALGB 10403 compared with COG AALL0232 (hyperglycemia, hyperbilirubinemia, transaminase elevation, and febrile neutropenia). Adverse events correlated with body mass index ≥30 kg/m2 and some with increasing age. The mortality rate in CALGB 10403 was low (4%) and similar to that in the COG AALL0232 trial. A caveat to this analysis is that only 39% of CALGB 10403 patients completed all planned protocol treatment. In COG AALL0232, although 74% of patients aged <18 years completed treatment, only 57% of patients aged ≥18 years completed treatment. This scenario suggests that issues associated with age and treating physician may be a factor. Due to its improved survival rates compared with historical controls, the CALGB 10403 regimen is now a standard of care. The hope is that the rate of protocol completion will increase as more familiarity is gained with this regimen. These trials were registered at www.clinicaltrials.gov as #NCT00558519 (CALGB 10403) and #NCT00075725 (COG AALL0232).
引用
- Advani AS, Larsen E, Laumann K, et al. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021. PMID: 33496745. doi:10.1182/bloodadvances.2020002439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。